Literature DB >> 12970898

Stability of randomly amplified polymorphic DNA fingerprinting in genotyping clinical isolates of Helicobacter pylori.

Feng-Chan Han1, Han-Chong Ng, Bow Ho.   

Abstract

AIM: H pylori genomes are highly diversified. This project was designed to genotype H pylori isolates by the polymerase chain reaction (PCR)-based randomly amplified polymorphic DNA (RAPD) fingerprinting technique and to verify its stability by Southern blotting and DNA sequencing.
METHODS: Clinical isolates of H pylori were cultured from gastric antra and cardia of 73 individuals, and genomic DNA was prepared for each isolate. RAPD was carried out under optimized conditions. 23S rDNA was regarded as an internal control, and a 361 bp rDNA fragment (RDF) was used as a probe to screen the RAPD products by Southern blotting. Ten RDFs from different clinical isolates and the flanking regions (both upstream and downstream) of four RDFs were amplified and sequenced.
RESULTS: H pylori isolates from different individuals had different RAPD profiles, but the profiles for isolates cultured from different gastric sites of a given individual were identical in all but one case. Isolates from 27 individuals were RDF positive by Southern blotting. Sequences of the RDFs and their flanking regions were almost the same between the RDF positive and negative isolates as determined by Southern blotting. There was no binding site for random PCR primer inside the sequences.
CONCLUSION: RAPD is very useful in genotyping H pylori grossly on a large scale. However, it seems unstable in amplification of low yield fragments, especially those that do not appear as visible bands on the agarose gel stained with EB, since the primer is partially matched to the template.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12970898      PMCID: PMC4656666          DOI: 10.3748/wjg.v9.i9.2021

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  38 in total

1.  Linking Helicobacter pylori to gastric cancer.

Authors:  M J Blaser
Journal:  Nat Med       Date:  2000-04       Impact factor: 53.440

2.  Gastric cancer and H pylori.

Authors:  S M Dawsey; S D Mark; P R Taylor; P J Limburg
Journal:  Gut       Date:  2002-09       Impact factor: 23.059

3.  Diversity of Helicobacter pylori genotypes among Estonian and Russian patients with perforated peptic ulcer, living in Southern Estonia.

Authors:  T Sillakivi; H Aro; M Ustav; M Peetsalu; A Peetsalu; M Mikelsaar
Journal:  FEMS Microbiol Lett       Date:  2001-02-05       Impact factor: 2.742

Review 4.  pathogenesis of Helicobacter pylori-induced gastric inflammation.

Authors:  D A Israel; R M Peek
Journal:  Aliment Pharmacol Ther       Date:  2001-09       Impact factor: 8.171

5.  Antibiotic susceptibility of Helicobacter pylori in the Chinese population.

Authors:  J Yakoob; X Fan; G Hu; L Liu; Z Zhang
Journal:  J Gastroenterol Hepatol       Date:  2001-09       Impact factor: 4.029

6.  Identification of a new segment involved in cagA 3' region variation of Helicobacter pylori.

Authors:  Quanjiang Dong; Maria O'Sullivan; Wendy Hall; Celine Herra; Conor Kean; Colm O'Morain; Martin Buckley
Journal:  FEMS Immunol Med Microbiol       Date:  2002-03-25

7.  Comparative genomics of the restriction-modification systems in Helicobacter pylori.

Authors:  L F Lin; J Posfai; R J Roberts; H Kong
Journal:  Proc Natl Acad Sci U S A       Date:  2001-02-13       Impact factor: 11.205

8.  Quasispecies development of Helicobacter pylori observed in paired isolates obtained years apart from the same host.

Authors:  E J Kuipers; D A Israel; J G Kusters; M M Gerrits; J Weel; A van Der Ende; R W van Der Hulst; H P Wirth; J Höök-Nikanne; S A Thompson; M J Blaser
Journal:  J Infect Dis       Date:  2000-01       Impact factor: 5.226

9.  Diversity of Helicobacter pylori among Chinese persons with H. pylori infection.

Authors:  J Yakoob; G L Hu; X G Fan; H X Yang; S H Liu; D M Tan; T G Li; Z Zhang
Journal:  APMIS       Date:  2000 Jul-Aug       Impact factor: 3.205

10.  16S rRNA mutation-mediated tetracycline resistance in Helicobacter pylori.

Authors:  Monique M Gerrits; Marcel R de Zoete; Niek L A Arents; Ernst J Kuipers; Johannes G Kusters
Journal:  Antimicrob Agents Chemother       Date:  2002-09       Impact factor: 5.191

View more
  7 in total

Review 1.  Relatedness of Helicobacter pylori populations to gastric carcinogenesis.

Authors:  Quan-Jiang Dong; Shu-Hui Zhan; Li-Li Wang; Yong-Ning Xin; Man Jiang; Shi-Ying Xuan
Journal:  World J Gastroenterol       Date:  2012-12-07       Impact factor: 5.742

Review 2.  Comparative genomics of Helicobacter pylori.

Authors:  Quan-Jiang Dong; Qing Wang; Ying-Nin Xin; Ni Li; Shi-Ying Xuan
Journal:  World J Gastroenterol       Date:  2009-08-28       Impact factor: 5.742

3.  Eradication Treatment of Helicobacter pylori Infection: Its Importance and Possible Relationship in Preventing the Development of Gastric Cancer.

Authors:  Bruna Maria Roesler; Sandra Cecília Botelho Costa; José Murilo Robilotta Zeitune
Journal:  ISRN Gastroenterol       Date:  2012-06-13

4.  Genomic variability of Helicobacter pylori isolates of gastric regions from two Colombian populations.

Authors:  Andrés Jenuer Matta; Alvaro Jairo Pazos; Javier Andrés Bustamante-Rengifo; Luis Eduardo Bravo
Journal:  World J Gastroenterol       Date:  2017-02-07       Impact factor: 5.742

Review 5.  Helicobacter pylori recrudescence and its influencing factors.

Authors:  Yan Sun; Jun Zhang
Journal:  J Cell Mol Med       Date:  2019-09-19       Impact factor: 5.310

Review 6.  Virulence Factors of Helicobacter pylori: A Review.

Authors:  Bruna M Roesler; Elizabeth M A Rabelo-Gonçalves; José M R Zeitune
Journal:  Clin Med Insights Gastroenterol       Date:  2014-03-27

Review 7.  Helicobacter pylori Infection, Virulence Genes' Distribution and Accompanying Clinical Outcomes: The West Africa Situation.

Authors:  Eric Gyamerah Ofori; Cynthia Ayefoumi Adinortey; Ansumana Sandy Bockarie; Foster Kyei; Emmanuel Ayitey Tagoe; Michael Buenor Adinortey
Journal:  Biomed Res Int       Date:  2019-12-10       Impact factor: 3.411

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.